Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Sanghoon Lee(The University of Texas MD Anderson Cancer Center), Li Zhao(The University of Texas MD Anderson Cancer Center), Christine Rojas(Inova Health System), Nicholas W. Bateman(Inova Health System), Hui Yao(The University of Texas MD Anderson Cancer Center), Olivia D. Lara(The University of Texas MD Anderson Cancer Center), Joseph Celestino(The University of Texas MD Anderson Cancer Center), Margaret Morgan(The University of Texas MD Anderson Cancer Center), Tri Nguyen(The University of Texas MD Anderson Cancer Center), Kelly A. Conrads(Inova Health System), Kelly M. Rangel(The University of Texas MD Anderson Cancer Center), Robert Dood(The University of Texas MD Anderson Cancer Center), Richard A. Hajek(The University of Texas MD Anderson Cancer Center), Gloria L. Fawcett(The University of Texas MD Anderson Cancer Center), Randy Chu(The University of Texas MD Anderson Cancer Center), Katlin N. Wilson(Inova Health System), Jeremy Loffredo(Inova Health System), Coralie Viollet(Henry M. Jackson Foundation), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Clifton L. Dalgard(Uniformed Services University of the Health Sciences), Xizeng Mao(The University of Texas MD Anderson Cancer Center), Xingzhi Song(The University of Texas MD Anderson Cancer Center), Ming Zhou(Inova Health System), Brian L. Hood(Inova Health System), Nirad Banskota(Inova Health System), Matthew D. Wilkerson(Henry M. Jackson Foundation), Jerez A. Te(Henry M. Jackson Foundation), Anthony R. Soltis(Henry M. Jackson Foundation), Kristin Roman(Akoya Biosciences (United States)), Andrew Dunn(Akoya Biosciences (United States)), David Cordover(Akoya Biosciences (United States)), Agda Karina Eterovic(The University of Texas MD Anderson Cancer Center), Jinsong Liu(The University of Texas MD Anderson Cancer Center), Jared K. Burks(The University of Texas MD Anderson Cancer Center), Keith Baggerly(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Robert L. Coleman(The University of Texas MD Anderson Cancer Center), Gordon B. Mills(The University of Texas MD Anderson Cancer Center), Yovanni Casablanca(Walter Reed National Military Medical Center), Jianhua Zhang(The University of Texas MD Anderson Cancer Center), Thomas P. Conrads(Inova Health System), G. Larry Maxwell(Inova Health System), P. Andrew Futreal(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center)
Cell Reports
April 1, 2020
10.1016/j.celrep.2020.03.066
Cited by 138Open Access
Full Text

Abstract

The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC), which is the most lethal gynecologic malignancy, is not well understood. Here, we perform comprehensive multi-platform omics analyses, including integrated analysis, and immune monitoring on primary and metastatic sites from highly clinically annotated HGSC samples based on a laparoscopic triage algorithm from patients who underwent complete gross resection (R0) or received neoadjuvant chemotherapy (NACT) with excellent or poor response. We identify significant distinct molecular abnormalities and cellular changes and immune cell repertoire alterations between the groups, including a higher rate of NF1 copy number loss, and reduced chromothripsis-like patterns, higher levels of strong-binding neoantigens, and a higher number of infiltrated T cells in the R0 versus the NACT groups.

Related Papers

No related papers found

Powered by citation graph analysis